ClinicalTrials.gg
RecruitingNCT06950294iNO300Updated May 22, 2026

iNO300 Therapy in Critically Ill Patients With Pneumonia

An Early Phase 1 interventional study of High dose inhaled nitric oxide and Sham treatment in Critical Illness and Pneumonia, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Primary conditionPneumoniaRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pneumonia
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Pneumonia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Massachusetts General Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 344 studies in Pneumonia with a site in United States — 40 open to participants now, 51 under way, 6 of them phase 3. Pneumonia · United States.

Planned enrollment
181st of 263
34 · median 91
Started
2026
with 12 others
Phase 1
29 of 344
2 open now
Primary completion
2026-12
later than 17 of 48 live
Registered
324th of 344
by date
Lead sponsor
6 of 344
Massachusetts General Hospital

Among the 344 studies in Pneumonia with a site in United States, this one is the 181st largest by planned enrollment of the 263 interventional ones that give a count, is one of 13 that started in 2026, is one of 29 in phase 1, reaches primary completion later than 17 of the 48 other live ones, and was the 324th registered.

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

40 of the 344 studies in Pneumonia with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 344 studies in Pneumonia with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn the formation and recovery rate of methemoglobin (MetHb) in severely sick patients with pneumonia who receive high doses of inhaled nitric oxide (iNO) therapy at 250 parts per million (ppm), not exceeding 300 ppm. Meanwhile, the benefits of the therapy to treat severely sick patients with pneumonia will be explored. Patients who are 18 years or older, newly diagnosed with pneumonia, and severely sick with requirement of a breathing machine could be included. The main questions it aims to answer are:

How does methemoglobin change through the iNO treatment? Does iNO therapy increase the number of patients recovering from pneumonia? Researchers will compare iNO treatment to placebo, which means using the same device as the treatment group without delivering the study drug.

Participants will:

  • Receive iNO treatment starting at 250 ppm, not exceeding 300 ppm, 40 min, every 6 hours, from day 1 to day 5
  • Be followed up for 60 days
Read the detailed description

This study is designed as a pilot, double-blinded, randomized controlled trial to investigate levels of methemoglobin in the treatment group versus the control group and efficacy of high dose inhaled NO among critically ill patients with pneumonia. We will enroll 34 adult patients with newly diagnosed pneumonia and invasive mechanical ventilation who are admitted to the ICUs at Massachusetts General Hospital.

After enrollment, participants will be randomized in 1:1 ratio to intervention group or control group. Baseline characteristics will be collected.

During treatment period, patients allocated to the intervention group will receive high dose inhaled NO starting at 250 ppm (not exceeding 300 ppm), 40min, 4 times daily, for 5 days. The control group will receive sham intervention. Both groups will receive standard therapy.

During follow-up period, we will follow participants for a total duration of 60 days. Methemoglobin kinetic levels and efficacy outcomes will be collected.

03

Conditions studied

  • Critical Illness
  • Pneumonia

Browse trials for

Keywords

  • High dose inhaled nitric oxide
  • Pneumonia
  • Critical care
  • Methemoglobin
04

In context

Pneumonia Reclassified

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

This study's planned enrollment of 34 is below the median of 128 across 978 interventional studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.

Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.

Compared within Pneumonia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Intubated and mechanically ventilated
  • Within 72h of diagnosis of community- or hospital-acquired pneumonia
  • Written obtained from patients or legally authorized representatives

Exclusion criteria

Exclusion Criteria:

  • Baseline methemoglobin 3% or higher
  • Genetic diseases including glucose-6-phosphate dehydrogenase deficiency, cytochrome b5 reductase deficiency, sickle cell disease
  • Oxygen saturation \< 88% on 100% inspired fraction of oxygen
  • Anemia with \< 7.0 g/dl
  • Acute cardiogenic shock requiring inotropic or mechanical support with an less than 20%
  • Receiving inhaled NO therapy or decision to initiate inhaled NO therapy within 24 hours post randomization
  • A decision to do-not-resuscitate (DNR)
  • Enrollment in another experimental antimicrobial treatment protocol
  • Patients for whom follow-up is expected to be impossible
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

06

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    iNO300 group

    High dose inhaled nitric oxide starting at 250 ppm (not exceeding 300 ppm) , 40min, 4 times daily, from day 1 to day 5. Nitric oxide is delivered using a gas cylinder containing nitric oxide and nitrogen.

    Drug: High dose inhaled nitric oxide · Other: standard therapy

  • Sham comparator
    Control group

    Sham intervention with the nitric oxide gas cylinder replaced by that containing only nitrogen and all other delivery procedures identical to the intervention group

    Other: Sham treatment · Other: standard therapy

Interventions

  • DrugNitric OxideStudies of Nitric OxideNitric Oxide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Inhaled nitric oxide starting at 250-300 ppm, 40min, every 6 hours, from day 1 to day 5. Nitric oxide is delivered using a gas cylinder containing nitric oxide and nitrogen.

  • OtherSham treatment

    Sham intervention with the nitric oxide gas cylinder replaced by that containing only nitrogen and all other delivery procedures identical to the intervention group

  • Otherstandard therapy

    Standard therapy pneumonia and critical illness

07

What researchers measure

Primary outcomes

  1. Peaks of methomoglobin

    Continuous recording of MetHb and peaks of MetHb will be determined.

    Time frame: From Day 1 to Day 5

Secondary outcomes

  1. Nitrogen dioxide level

    Continuous measurement of nitrogen dioxide concentration in the inspiratory limb of breathing circuit

    Time frame: From Day 1 to Day 5

  2. Feasibility

    Referral, recruitment, retention, compliance and follow-up completion rates of the study

    Time frame: From enrollment to Day 60

  3. Clinical cure rate of pneumonia

    Clinical cure is assessed at test of cure (4 -11 days post end of treatment) and defined as resolution of clinical signs and symptoms of pneumonia compared with baseline, including a reduction in SOFA and CPIS scores, improvement or lack of progression in chest imaging, and no requirement for additional antibacterial treatment.

    Time frame: From enrollment to test of cure day (4 -11 days post end of treatment)

  4. Clinical improvement rate of pneumonia

    Clinical improvement is assessed at end of treatment and defined as improvement in 2 or more clinical signs and symptoms of pneumonia compared with baseline, improvement or lack of progression of chest x-ray abnormalities, and no requirement for additional antibacterial treatment. Clinical signs and symptoms of pneumonia include new onset or worsening cough, purulent sputum or increased suction requirements, auscultation findings of pneumonia, dyspnea, tachypnea, or respiratory rate ≥ 30/min, hypoxemia, worsening gas exchange.

    Time frame: Day 5

  5. Microbiologic eradication rate

    Absence of the baseline pathogen from tracheal aspiration or bronchoalveolar lavage fluid will be confirmed. If it is not possible to obtain an appropriate clinical specimen for culture and the patient has a successful clinical outcome, the response was presumed to be eradication.

    Time frame: From enrollment to test of cure day (4 -11 days post end of treatment)

  6. 28-day all cause mortality

    All cause mortality from enrollment to Day 28

    Time frame: From enrollment to Day 28

  7. 60-day all cause mortality

    All cause mortality from enrollment to Day 60

    Time frame: From enrollment to Day 60

  8. 28-day ventilator free days

    Successful liberation from mechanical ventilation should last more than 48 h without re-intubation in patients who have survived 28 days after randomization (extubation was counted from the last successful attempt in patients who have survived 28 days since randomization) and for patients ventilated for 28 days or more or who died before 28 days (irrespective of intubation status), the number of ventilator-free days was recorded at zero.

    Time frame: From enrollment to Day 28

  9. Days free from organ support in 28 days

    Organ support includes mechanical ventilation, vasopressors and renal replacement therapy.

    Time frame: From enrollment to Day 28

  10. Blood stream infection

    Positive blood culture with a pathogenic bacterium

    Time frame: From enrollment to Day 28

  11. Days free from antibiotics during hospitalization

    Days free from antibiotics during hospitalization

    Time frame: From enrollment to the day of hospital discharge or death, whichever comes earlier, assessed up to 60 days

  12. Acquisition of multidrug-resistant (MDR) infection or colonization

    Multidrug-resistant infection is defined as pathogen acquiring non-susceptibility to at least one agent in three or more antibiotic categories

    Time frame: From enrollment to Day 28

  13. Hospital stay

    Days from enrollment to the end of hospitalization

    Time frame: From enrollment to the day of hospital discharge or death, whichever comes earlier, assessed up to 60 days

  14. ICU length of stay

    ICU length of stay

    Time frame: From enrollment to the day of ICU discharge or death, whichever comes earlier, assessed up to 60 days

  15. Inflammatory markers

    The test includes C reactive protein (CRP), procalcitonin (PCT), monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor α (TNF α), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10).

    Time frame: From enrollment to test of cure (4-11 days post end of treatment)

  16. Relapse rate

    Relapse is assessed for patients with hospital-acquired pneumonia at 28-day follow-up after test of cure and defined as recurrence or new appearance of at least two of the three symptoms and signs (fever greater than 38 °C, leukocytosis or leukopenia, and purulent tracheobronchial secretions), along with a new or persistent infiltrate on chest radiography in a patient assessed as clinical cure at TOC.

    Time frame: From enrollment to Day 28

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Tal A, Greenberg D, Av-Gay Y, Golan-Tripto I, Feinstein Y, Ben-Shimol S, Dagan R, Goldbart AD. Nitric oxide inhalations in bronchiolitis: A pilot, randomized, double-blinded, controlled trial. Pediatr Pulmonol. 2018 Jan;53(1):95-102. doi: 10.1002/ppul.23905. Epub 2017 Nov 27. PubMed 29178284 ↗
  • Wolak T, Dicker D, Shifer Y, Grossman A, Rokach A, Shitrit M, Tal A. A safety evaluation of intermittent high-dose inhaled nitric oxide in viral pneumonia due to COVID-19: a randomised clinical study. Sci Rep. 2024 Jul 26;14(1):17201. doi: 10.1038/s41598-024-68055-w. PubMed 39060420 ↗
  • Miller C, Miller M, McMullin B, Regev G, Serghides L, Kain K, Road J, Av-Gay Y. A phase I clinical study of inhaled nitric oxide in healthy adults. J Cyst Fibros. 2012 Jul;11(4):324-31. doi: 10.1016/j.jcf.2012.01.003. Epub 2012 Apr 18. PubMed 22520076 ↗
  • Wiegand SB, Safaee Fakhr B, Carroll RW, Zapol WM, Kacmarek RM, Berra L. Rescue Treatment With High-Dose Gaseous Nitric Oxide in Spontaneously Breathing Patients With Severe Coronavirus Disease 2019. Crit Care Explor. 2020 Nov 16;2(11):e0277. doi: 10.1097/CCE.0000000000000277. eCollection 2020 Nov. PubMed 33225304 ↗
  • Strickland B, Albala L, Coffey EC, Carroll RW, Zapol WM, Ichinose F, Berra L, Harris NS. Safety and practicality of high dose inhaled nitric oxide in emergency department COVID-19 patients. Am J Emerg Med. 2022 Aug;58:5-8. doi: 10.1016/j.ajem.2022.04.052. Epub 2022 May 4. PubMed 35623183 ↗
  • Safaee Fakhr B, Di Fenza R, Gianni S, Wiegand SB, Miyazaki Y, Araujo Morais CC, Gibson LE, Chang MG, Mueller AL, Rodriguez-Lopez JM, Ackman JB, Arora P, Scott LK, Bloch DB, Zapol WM, Carroll RW, Ichinose F, Berra L; Nitric Oxide Study Investigators. Inhaled high dose nitric oxide is a safe and effective respiratory treatment in spontaneous breathing hospitalized patients with COVID-19 pneumonia. Nitric Oxide. 2021 Nov 1;116:7-13. doi: 10.1016/j.niox.2021.08.003. Epub 2021 Aug 13. PubMed 34400339 ↗
  • Wiegand SB, Traeger L, Nguyen HK, Rouillard KR, Fischbach A, Zadek F, Ichinose F, Schoenfisch MH, Carroll RW, Bloch DB, Zapol WM. Antimicrobial effects of nitric oxide in murine models of Klebsiella pneumonia. Redox Biol. 2021 Feb;39:101826. doi: 10.1016/j.redox.2020.101826. Epub 2020 Dec 11. PubMed 33352464 ↗
  • Valsecchi C, Winterton D, Safaee Fakhr B, Collier AY, Nozari A, Ortoleva J, Mukerji S, Gibson LE, Carroll RW, Shaefi S, Pinciroli R, La Vita C, Ackman JB, Hohmann E, Arora P, Barth WH Jr, Kaimal A, Ichinose F, Berra L; DELiverly oF iNO (DELFiNO) Network Collaborators. High-Dose Inhaled Nitric Oxide for the Treatment of Spontaneously Breathing Pregnant Patients With Severe Coronavirus Disease 2019 (COVID-19) Pneumonia. Obstet Gynecol. 2022 Aug 1;140(2):195-203. doi: 10.1097/AOG.0000000000004847. Epub 2022 Jul 6. PubMed 35852269 ↗
  • Bartley BL, Gardner KJ, Spina S, Hurley BP, Campeau D, Berra L, Yonker LM, Carroll RW. High-Dose Inhaled Nitric Oxide as Adjunct Therapy in Cystic Fibrosis Targeting Burkholderia multivorans. Case Rep Pediatr. 2020 Jun 24;2020:1536714. doi: 10.1155/2020/1536714. eCollection 2020. PubMed 32685229 ↗
  • Okda M, Spina S, Safaee Fakhr B, Carroll RW. The antimicrobial effects of nitric oxide: A narrative review. Nitric Oxide. 2025 Apr;155:20-40. doi: 10.1016/j.niox.2025.01.001. Epub 2025 Jan 8. PubMed 39793728 ↗

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Beginning 1 year after publication with no end date

Access criteria: A proposal that describes planned analyses must be submitted to the principal investigator via email. Data sharing agreement should be reached, documented and signed.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 35 phase 1 interventional studies under Pneumonia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 34. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2025
First posted
Apr 30, 2025
StartActual
Feb 23, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06950294
Responsible party
Lorenzo Berra, MD (Clinician Investigator, Associate Professor, Anesthesia, Critical Care and Pain Medicine, Mass General Research Institute, Massachusetts General Hospital) — Principal investigator
First posted
Apr 30, 2025
Start date
Feb 23, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 22, 2026

Study contacts

Lorenzo Berra, MD
Contact
lberra@mgh.harvard.edu
617-726-3030
Run Dong, MD
Contact
rdong2@mgh.harvard.edu
617-726-3030
Lorenzo Berra, MD
principal investigator · Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitric Oxide

Start the discussion